|
Notifying FDA of a Discontinuance or Interruption in Manufacturing
|
|
0
|
273
|
February 7, 2024
|
|
TGA (Australia) :australia: Updates Published Acceptable Intakes
|
|
3
|
983
|
February 7, 2024
|
|
The effect of nitrite and nitrate presence in raw materials on nitrosamine risk
|
|
15
|
3577
|
February 6, 2024
|
|
Mechanisms of Nitrosamine Mutagenicity and Their Relationship to Rodent Carcinogenic Potency -Pub
|
|
0
|
699
|
February 6, 2024
|
|
Metabolic activation of short-chain alkyl N-nitrosamines using Aroclor 1254 or phenobarbital/beta-naphthoflavone-induced rat or hamster S9 – a comparative analysis -Pub
|
|
4
|
481
|
February 2, 2024
|
|
Aromatic nitrogen "Is it possible for aromatic nitrogen to convert nitrosamine?"- Indole
|
|
10
|
2619
|
February 2, 2024
|
|
Nitrosamine Impurities in Topical Drug Product
|
|
3
|
660
|
February 3, 2024
|
|
Patient In-Use Stability Testing of FDA-Approved Metformin Combination Products for N-Nitrosamine Impurity
|
|
6
|
679
|
January 31, 2024
|
|
Adoption of CPCA beyond FDA/ EMA
|
|
9
|
1049
|
January 31, 2024
|
|
Nitrosamines from polybags to finished product
|
|
4
|
1198
|
January 31, 2024
|
|
🇪🇺 EMA/409815/2020 Rev.20
|
|
7
|
5794
|
January 31, 2024
|
|
Imidazole is a secondary amine?
|
|
16
|
3733
|
January 30, 2024
|
|
Sixth Nitrosamine Implementation Oversight Group (NIOG) - meeting with pharmaceutical industry
|
|
4
|
666
|
January 30, 2024
|
|
N-nitroso Vonoprazan AI 96 ng/day- FDA
|
|
5
|
4194
|
January 29, 2024
|
|
Limit for NDSRI
|
|
3
|
1521
|
January 29, 2024
|
|
Updated EMA-Acceptable intakes (AIs) established for N-nitrosamines
|
|
20
|
6602
|
January 29, 2024
|
|
Microcalorimetry to explore reactivity, anybody?
|
|
1
|
269
|
January 26, 2024
|
|
📰 Nitrosamine measures might disrupt anesthetic supply, Dr. Eric Tichy says
|
|
4
|
569
|
January 26, 2024
|
|
Isoniazid nitrosamine formation
|
|
0
|
413
|
January 25, 2024
|
|
How to identify NDSRI for an API
|
|
5
|
871
|
January 24, 2024
|
|
📚 OPRD Special Issue on Nitrosamines -Pub
|
|
13
|
2688
|
January 23, 2024
|
|
Nitrosamines risk assessment and batch results
|
|
4
|
636
|
January 23, 2024
|
|
🇬🇧 Medicines: MAH' submission of Nitrosamine risk evaluation, risk assessment and confirmatory testing
|
|
2
|
1087
|
January 23, 2024
|
|
Duplex Sequencing - Future of mutagenicity assessment
|
|
3
|
639
|
January 23, 2024
|
|
European Pharmacopeia - Open for comments 'N-Nitrosamines in active substance and medicinal products'
|
|
0
|
714
|
December 19, 2023
|
|
LC/Q-TOF-MS-based structural characterization of enasidenib degradation products and establishment of a stability-indicating assay method: Insights into chemical stability -Pub
|
|
0
|
279
|
January 23, 2024
|
|
The comprehensive prediction of carcinogenic potency and tumorigenic dose (TD50) for two problematic N-nitrosamines in food: NMAMPA and NMAMBA using toxicology in silico methods -Pub
|
|
0
|
289
|
January 23, 2024
|
|
FDA leaders detail reorg plans Webinar
|
|
0
|
291
|
January 23, 2024
|
|
A quick (dumb) question
|
|
10
|
1415
|
January 22, 2024
|
|
🇪🇺 Ph. Eur. Commission adopts revised general monographs 2034 and 2619 after inclusion of new paragraph on control of N-nitrosamines
|
|
1
|
969
|
January 22, 2024
|